<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who had false positive results on 18-fluorodeoxyglucose <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (FDG-PET) tests for more than six months due to inflammatory reactions continuing over a long period of time after chemotherapy with rituximab </plain></SENT>
<SENT sid="1" pm="."><plain>Although FDG-PET has advantages over other imaging methods when used for the evaluation of the response to chemotherapy and detection of recurrence, attention should be paid to the possibility of false positive results due to such inflammatory conditions, especially when rituximab is administered </plain></SENT>
<SENT sid="2" pm="."><plain>Biopsy of the FDG-uptake lesions is strongly recommended if recurrence is suspected </plain></SENT>
</text></document>